Last reviewed · How we verify

Artemether 20 mg-Lumefantrine 120 mg

University of Oxford · FDA-approved active Small molecule Quality 5/100

Artemether 20 mg-Lumefantrine 120 mg is a Small molecule drug developed by University of Oxford. It is currently FDA-approved.

At a glance

Generic nameArtemether 20 mg-Lumefantrine 120 mg
SponsorUniversity of Oxford
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Artemether 20 mg-Lumefantrine 120 mg

What is Artemether 20 mg-Lumefantrine 120 mg?

Artemether 20 mg-Lumefantrine 120 mg is a Small molecule drug developed by University of Oxford.

Who makes Artemether 20 mg-Lumefantrine 120 mg?

Artemether 20 mg-Lumefantrine 120 mg is developed and marketed by University of Oxford (see full University of Oxford pipeline at /company/university-of-oxford).

What development phase is Artemether 20 mg-Lumefantrine 120 mg in?

Artemether 20 mg-Lumefantrine 120 mg is FDA-approved (marketed).

Related